Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you decide between infusional 5-FU and oral capecitabine for patients undergoing neoadjuvant chemoradiation for rectal cancer?
Related Questions
For T3N0 rectosigmoid tumors who get surgery upfront, what is your preferred adjuvant therapy?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
How would you approach a gastric GIST with R1 resection?
Would you treat an unresectable MSI-H colon cancer patient with persistent hepatitis C with immunotherapy?
When do you consider performing a diagnostic laparoscopy before neoadjuvant chemotherapy in pancreatic adenocarcinoma patients?
Would you offer chemotherapy to an elderly patient with MSI-H stage 3 colon cancer who cannot tolerate oxaliplatin?
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
Would you consider Trastuzumab Deruxtecan as a second line option for metastatic HER2+ squamous cell carcinoma of the esophagus after progression on FOLFOX + Nivolumab?
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?
How do you approach patients with unresectable pancreatic cancer on gemcitabine/nab-paclitaxel-based chemotherapy q28 days with severe neutropenia?
